Ivax Launch Of Generic Neurontin Raises Eyebrows

Law360, New York (August 19, 2004, 12:00 AM EDT) -- Ivax Corp.’s decision Wednesday to launch a generic version of Pfizer Inc.'s blockbuster epilepsy drug Neurontin in the midst of a drawn-out patent dispute is seen by analysts as a bold but risky move.

Ivax said Wednesday that it was carrying out only a "limited" launch to a small number of buyers, most likely pharmacy-benefit managers and managed-care organizations.

Under most state pharmacy laws, Ivax's generic tablet may not technically be substitutable for Pfizer's Neurontin in the same strengths, given that it is a tablet formulation...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.